This article is part of the supplement: Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008 .

Meeting abstract

New insights on low-grade and T-cell lymphoma

William Tse

University of Colorado Cancer Center, Denver, CO, USA

author email corresponding author email

from Current trends in leukemia, lymphoma and myeloma
White Plains, NY, USA. 31 January 2009

Journal of Hematology & Oncology 2009, 2(Suppl 1):A3doi:10.1186/1756-8722-2-S1-A3

The electronic version of this abstract is the complete one and can be found online at: http://www.jhoonline.org/content/2/S1/A3

Published:

26 June 2009

© 2009 Tse; licensee BioMed Central Ltd.

Meeting abstract

The advances in low-grade lymphoma & T-cell lymphoma from the 2008 ASH meeting were presented. These included therapeutic regimens for low grade lymphoma, frontline bendamustine plus rituximab data, radioimmunotherapy consolidation in advanced disease, idiotype vaccine, and other novel therapeutic agents such as next generation anti-CD20 GA101, syk inhibitor Fostamatinib in treatment of low-grade lymphoma. In T-cell lymphoma, updates were discussed on phase II HOVON 69 trial data of combination of alemtuzumab/CHOP, pralatrexate and romidepsin for relapsed/refractory PTCL, L-asparaginase-containing regimen for extranodal NK/T-cell lymphoma.

Have something to say? Post a comment on this article!